{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:46:48Z","timestamp":1795110408717,"version":"4.10.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Canadian Partnership Against Cancer Corporation www.partnershipagainstcancer.ca"},{"name":"Canadian Partnership Against Cancer Corporation https:\/\/www.partnershipagainstcancer.ca\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A decision analytic model was completed from the healthcare payer\u2019s perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (<jats:italic>n<\/jats:italic>\u2009=\u20091040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC\u2009+\u2009SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC\u2009+\u2009SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC\u2009+\u2009SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC\u2009+\u2009SSM. Both were cost-effective in 100% of 1000 simulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Given the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-024-02819-z","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T22:01:46Z","timestamp":1723672906000},"page":"1178-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-effectiveness of point of care smoking cessation interventions in oncology clinics"],"prefix":"10.1038","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-4486","authenticated-orcid":false,"given":"Kerri A.","family":"Mullen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Hewitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Scoville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kednapa","family":"Thavorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshwar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham W.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2819_CR1","unstructured":"Canadian Thoracic Society. The Human and Economic Burden of COPD: A Leading Cause of Hospital Admission in Canada. 2010. Available from: www.lung.ca\/cts-sct\/pdf\/COPDReport_E.pdf."},{"key":"2819_CR2","doi-asserted-by":"crossref","unstructured":"Lightwood J, Collins, D, Lapsley H, Novotny TE. Estimating the costs of tobacco use. In: Jha P, Chaloupka, K, editor. Tobacco Control in Developing Countries. Cary, ND: Oxford University Press; 2000.","DOI":"10.1093\/oso\/9780192632500.003.0004"},{"key":"2819_CR3","unstructured":"Public Health Agency of Canada. Tracking Heart Disease and Stroke in Canada 2009 October 28. 2013. Available from: www.phac-aspc.gc.ca\/publicat\/2009\/cvd-avc\/pdf\/cvd-avs-2009-eng.pdf."},{"key":"2819_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/tobaccocontrol-2015-052728","volume":"26","author":"KA Mullen","year":"2017","unstructured":"Mullen KA, Manuel DG, Hawken SJ, Pipe AL, Coyle D, Hobler LA, et al. Effectiveness of a hospital-initiated smoking cessation programme: 2-year health and healthcare outcomes. Tob Control. 2017;26:293\u20139.","journal-title":"Tob Control"},{"key":"2819_CR5","unstructured":"Department of Health and Human Services CfDCaP, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. 2014. Available from: https:\/\/www.hhs.gov\/surgeongeneral\/not-found\/library\/reports\/50-years-of-progress\/front-matter.pdf."},{"key":"2819_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.oraloncology.2006.02.006","volume":"43","author":"K Jensen","year":"2007","unstructured":"Jensen K, Jensen AB, Grau C. Smoking has a negative impact upon health related quality of life after treatment for head and neck cancer. Oral Oncol. 2007;43:187\u201392.","journal-title":"Oral Oncol"},{"key":"2819_CR7","doi-asserted-by":"publisher","first-page":"b5569","DOI":"10.1136\/bmj.b5569","volume":"340","author":"A Parsons","year":"2010","unstructured":"Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340:b5569.","journal-title":"BMJ"},{"key":"2819_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1759-7714.13852","volume":"12","author":"A Cortellini","year":"2021","unstructured":"Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, Baldessari C, et al. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. Thorac Cancer. 2021;12:880\u20139.","journal-title":"Thorac Cancer"},{"key":"2819_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/hed.10168","volume":"24","author":"GP Browman","year":"2002","unstructured":"Browman GP, Mohide EA, Willan A, Hodson I, Wong G, Grimard L, et al. Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. Head Neck. 2002;24:1031\u20137.","journal-title":"Head Neck"},{"key":"2819_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000319937","volume":"78","author":"JK Cataldo","year":"2010","unstructured":"Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology. 2010;78:289\u2013301.","journal-title":"Oncology"},{"key":"2819_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000489266","volume":"95","author":"EG Kaiser","year":"2018","unstructured":"Kaiser EG, Prochaska JJ, Kendra MS. Tobacco Cessation in Oncology Care. Oncology. 2018;95:129\u201337.","journal-title":"Oncology"},{"key":"2819_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMsa1211128","volume":"368","author":"P Jha","year":"2013","unstructured":"Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-Century Hazards of Smoking and Benefits of Cessation in the United States. N. Engl J Med. 2013;368:341\u201350.","journal-title":"N. Engl J Med"},{"key":"2819_CR13","unstructured":"U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. 2014. Available from: www.surgeongeneral.gov\/library\/reports\/50-years-of-progress\/front-matter.pdf."},{"key":"2819_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3322\/caac.21231","volume":"64","author":"M Karam-Hage","year":"2014","unstructured":"Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64:272\u201390.","journal-title":"CA Cancer J Clin"},{"key":"2819_CR15","first-page":"180","volume":"71","author":"VW Li","year":"2018","unstructured":"Li VW, Lam J, Heise P, Reid RD, Mullen KA. Implementation of a Pharmacist-Led Inpatient Tobacco Cessation Intervention in a Rehabilitation Hospital: A Before-and-After Pilot Study. Can J Hospital Pharm. 2018;71:180\u20136.","journal-title":"Can J Hospital Pharm"},{"key":"2819_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1370\/afm.1909","volume":"14","author":"S Papadakis","year":"2016","unstructured":"Papadakis S, Cole AG, Reid RD, Coja M, Aitken D, Mullen KA, et al. Increasing Rates of Tobacco Treatment Delivery in Primary Care Practice: Evaluation of the Ottawa Model for Smoking Cessation. Ann Fam Med. 2016;14:235\u201343.","journal-title":"Ann Fam Med"},{"key":"2819_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2337\/dc17-1809","volume":"41","author":"RD Reid","year":"2018","unstructured":"Reid RD, Malcolm J, Wooding E, Geertsma A, Aitken D, Arbeau D, et al. Prospective, Cluster-Randomized Trial to Implement the Ottawa Model for Smoking Cessation in Diabetes Education Programs in Ontario, Canada. Diab Care. 2018;41:406\u201312.","journal-title":"Diab Care"},{"key":"2819_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ntr\/ntp165","volume":"12","author":"RD Reid","year":"2010","unstructured":"Reid RD, Mullen KA, Slovinec D\u2019Angelo ME, Aitken DA, Papadakis S, Haley PM, et al. Smoking cessation for hospitalized smokers: an evaluation of the \u201cOttawa Model\u201d. Nicotine Tob Res. 2010;12:11\u20138.","journal-title":"Nicotine Tob Res"},{"key":"2819_CR19","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.1503\/cjs.009919","volume":"64","author":"J Sadek","year":"2021","unstructured":"Sadek J, Moloo H, Belanger P, Nadeau K, Aitken D, Foss K, et al. Implementation of a systematic tobacco treatment protocol in a surgical outpatient setting: a feasibility study. Can J Surg J Can Chirurgie. 2021;64:E51\u2013e8.","journal-title":"Can J Surg J Can Chirurgie"},{"key":"2819_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/tobaccocontrol-2013-051483","volume":"24","author":"KA Mullen","year":"2015","unstructured":"Mullen KA, Coyle D, Manuel D, Nguyen HV, Pham B, Pipe AL, et al. Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada. Tob Control. 2015;24:489\u201396.","journal-title":"Tob Control"},{"key":"2819_CR21","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.3390\/cancers13174272","volume":"13","author":"F Toscano","year":"2021","unstructured":"Toscano F, Vera A, Kim E, Golinelli D, Vila-Reyes H. The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine. Cancers. 2021;13:4272.","journal-title":"Cancers"},{"key":"2819_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpopen.2021.100063","volume":"3","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Health Policy OPEN. 2022;3:100063.","journal-title":"Health Policy OPEN"},{"key":"2819_CR23","unstructured":"Statistics Canada. Table 13-10-0111-01 Number and rates of new cases of primary cancer, by cancer type, age group and sex. 2021. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011101."},{"key":"2819_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3747\/co.27.5951","volume":"27","author":"N Iragorri","year":"2020","unstructured":"Iragorri N, Essue B, Timmings C, Keen D, Bryant H, Warren GW. The cost of failed first-line cancer treatment related to continued smoking in Canada. Curr Oncol. 2020;27:307\u201312.","journal-title":"Curr Oncol"},{"key":"2819_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0306-4603(78)90024-2","volume":"3","author":"KO Fagerstrom","year":"1978","unstructured":"Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3:235\u201341.","journal-title":"Addict Behav"},{"key":"2819_CR26","unstructured":"Ontario Tobacco Research Unit. Data Standards for Smoke-Free Ontario Smoking Cessation Service Providers 2013 December 29. 2021. Available from: https:\/\/www.otru.org\/wp-content\/uploads\/2013\/08\/special_data_standards.pdf."},{"key":"2819_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1360-0443.2004.00995.x","volume":"100","author":"R West","year":"2005","unstructured":"West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100:299\u2013303.","journal-title":"Addiction"},{"key":"2819_CR28","unstructured":"Government of Canada. Respiratory Therapist in Canada; Prevailing wages in Canada 2020 April 1. 2023. Available from: https:\/\/www.jobbank.gc.ca\/marketreport\/wages-occupation\/22786\/ca."},{"key":"2819_CR29","unstructured":"Government of Canada. Wages for Registered nurses and registered psychiatric nurses 2020 April 10. 2023. Available from: https:\/\/www.jobbank.gc.ca\/wagereport\/occupation\/993."},{"key":"2819_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/13696998.2021.1917139","volume":"24","author":"MA Chaudhary","year":"2021","unstructured":"Chaudhary MA, Holmberg C, Lakhdari K, Smare C, Theriou C, Dale P, et al. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data. J Med Econ. 2021;24:607\u201319.","journal-title":"J Med Econ"},{"key":"2819_CR31","doi-asserted-by":"publisher","first-page":"viii434","DOI":"10.1093\/annonc\/mdy288.094","volume":"29","author":"K Virik","year":"2018","unstructured":"Virik K, Wilson RB. Potential drug cost impact of dual agent immunotherapy (DAIO) with nivolumab (N) plus ipilimumab (I) in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) in Canada. Ann Oncol. 2018;29:viii434.","journal-title":"Ann Oncol"},{"key":"2819_CR32","doi-asserted-by":"publisher","first-page":"E191","DOI":"10.9778\/cmajo.20190114","volume":"8","author":"N Mittmann","year":"2020","unstructured":"Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, et al. Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ Open. 2020;8:E191\u2013E8.","journal-title":"CMAJ Open"},{"key":"2819_CR33","doi-asserted-by":"publisher","first-page":"e001105","DOI":"10.1136\/bmjresp-2021-001105","volume":"8","author":"M Evison","year":"2021","unstructured":"Evison M, Cox J, Howle F, Groom K, Moore R, Clegg H, et al. Health economic analysis for the \u2018CURE Project\u2019 pilot: a hospital-based tobacco dependency treatment service in Greater Manchester. BMJ Open Respir Res. 2021;8:e001105.","journal-title":"BMJ Open Respir Res"},{"key":"2819_CR34","doi-asserted-by":"publisher","first-page":"e2216362","DOI":"10.1001\/jamanetworkopen.2022.16362","volume":"5","author":"DE Levy","year":"2022","unstructured":"Levy DE, Regan S, Perez GK, Muzikansky A, Friedman ER, Rabin J, et al. Cost-effectiveness of Implementing Smoking Cessation Interventions for Patients With Cancer. JAMA Netw open. 2022;5:e2216362\u2013e.","journal-title":"JAMA Netw open"},{"key":"2819_CR35","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2020.14581","volume":"324","author":"ER Park","year":"2020","unstructured":"Park ER, Perez GK, Regan S, Muzikansky A, Levy DE, Temel JS, et al. Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial. JAMA. 2020;324:1406\u201318.","journal-title":"JAMA"},{"key":"2819_CR36","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/jnci\/djab002","volume":"113","author":"CJ Cadham","year":"2021","unstructured":"Cadham CJ, Cao P. Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study. J Natl Cancer Inst. 2021;113:1065\u201373.","journal-title":"J Natl Cancer Inst"},{"key":"2819_CR37","doi-asserted-by":"publisher","first-page":"E585","DOI":"10.9778\/cmajo.20190134","volume":"8","author":"WK Evans","year":"2020","unstructured":"Evans WK, Gauvreau CL, Flanagan WM, Memon S, Yong JHE, Goffin JR, et al. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model. CMAJ Open. 2020;8:E585\u2013E92.","journal-title":"CMAJ Open"},{"key":"2819_CR38","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/curroncol29030130","volume":"29","author":"SA Santi","year":"2022","unstructured":"Santi SA, Conlon MSC, Meigs ML, Davidson SM, Mispel-Beyer K, Saunders DP. Rates of Smoking Cessation at 6 and 12 Months after a Clinical Tobacco Smoking Cessation Intervention in Head and Neck Cancer Patients in Northern Ontario, Canada. Curr Oncol. 2022;29:1544\u201358.","journal-title":"Curr Oncol"},{"key":"2819_CR39","doi-asserted-by":"crossref","unstructured":"A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. Am J Prevent Med. 2008;35:158\u201376.","DOI":"10.1016\/j.amepre.2008.04.009"},{"key":"2819_CR40","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1016\/j.jacc.2018.10.027","volume":"72","author":"RS Barua","year":"2018","unstructured":"Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri M-A, Morris PB, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment. J Am Coll Cardiol. 2018;72:3332\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"2819_CR41","unstructured":"Centers for Disease Control and Prevention. Clinical Interventions to Treat Tobacco Use and Dependence Among Adults 2021 April 13. 2023. Available from: https:\/\/www.cdc.gov\/tobacco\/patient-care\/care-settings\/clinical\/index.html."},{"key":"2819_CR42","doi-asserted-by":"publisher","first-page":"E484","DOI":"10.1503\/cmaj.151510","volume":"188","author":"RD Reid","year":"2016","unstructured":"Reid RD, Pritchard G, Walker K, Aitken D, Mullen KA, Pipe AL. Managing smoking cessation. CMAJ. 2016;188:E484\u2013E92.","journal-title":"CMAJ"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02819-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02819-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02819-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T15:31:39Z","timestamp":1739547099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02819-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10,19]]}},"alternative-id":["2819"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02819-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KAM is an inventor of the Ottawa Model for Smoking Cessation, a registered trademark of the University of Ottawa Heart Institute. KH, SH, and JS are staff of Horizon Health Network\u2019s Centre of Excellence for Clinical Smoking Cessation. EK is Medical Officer with the New Brunswick Cancer Network. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be considered a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project was approved by the Horizon Health Network Research Ethics Board (RS# 2021-2976). Retrospective program evaluation data were used; therefore, individual consent was not required. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}